Shilpa Medicare’s arm gets UK MHRA approval for Imatinib oral solution

07 Apr 2020 Evaluate

Shilpa Medicare through its UK subsidiary Koanaa Healthcare, has received UK MHRA approval for Imatinib oral solution. The approval of Imatinib Oral Solution represents a major step forward in treatment options for cancers in pediatric and geriatric patients, patients with swallowing difficulties and also offers dose titration across the patient population.

Imatinib Oral Solution, a first of its kind in the world, is the only approved product which facilitates accurate dose titrations and avoids unnecessary overdosing due to fixed doses, 100 mg and 400 mg, in the presently available marketed tablets. Imatinib Oral Solution is available as 80mg/mL. Imatinib Oral Solution is expected to be available in the UK in the second quarter of 2020 will be supplied from a UK based state of the art manufacturing facility LM pharmaceuticals. Imatinib Oral Solution is an innovative product and is expected to have patent protection until 2038.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

315.85 -4.50 (-1.40%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 901.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×